相关实验视频

Updated: Jun 21, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

转录基因分析揭示了与肺腺癌细胞系对向治疗的内在抵抗相关的早期变化

Mario Perez-Medina^1,2, Jose S Lopez-Gonzalez¹, Jesus J Benito-Lopez^1,3

¹Laboratorio de Cancer Pulmonar, Departamento de Enfermedades Cronico-Degenerativas, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Ciudad de Mexico 14080, Mexico.

|July 13, 2024

概括

过度表达的长非编码RNAs (lncRNAs) 在肺腺癌中驱动耐药性. 针对这些lncRNA和CD74mRNA可以改善肺癌患者的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学是一个遗传学.

背景情况:

肺腺癌 (LUAD) 是癌症死亡的主要原因.
在LUAD中的耐药性限制了治疗的有效性.
耐药性持续性 (DTP) 细胞有助于治疗失败.

研究的目的:

研究长非编码RNAs (lncRNAs) 在LUAD内固有的耐药性中的作用.
确定DTP细胞存活的基础分子机制.
评估在LUAD中 lncRNAs 的临床相关性.

主要方法:

已建立的DTP细胞来自LUAD细胞系,使用氨酸激酶抑制剂 (TKI).
进行RNA测序以分析DTP细胞中的IncRNA表达.
在患者队列 (TCGA) 和DTP细胞中通过RT-qPCR验证了lncRNA和mRNA的过度表达.

主要成果:

在 DTP 细胞中发现了特定 lncRNA 和 CD74 mRNA 的过度表达.
在LUAD患者样本中确认了lncRNAs的临床相关性.
证明了 lncRNA 倒置增强了 DTP 细胞对 TKI 的敏感性.

结论:

lncRNAs与LUAD的内在耐药性有关.
过度表达的lncRNAs和CD74mRNA代表了潜在的预后生物标志物.
针对已识别的lncRNAs提供了一种治疗策略,以克服耐药性并改善患者的存活率.

关键词:

CD74 CD74 CD74 CD74 CD74 CD74 CD74 CD74 CD74 CD74 CD74 CD74 耐药性持续性 (DTP) 细胞是耐药性的细胞.埃尔洛丁尼布 (erlotinib) 是一种药物.内在电阻是一种内在电阻.肺部腺癌的癌症.奥西米尔丁尼布 (osimertinib) 是一种衰老细胞是老化的细胞.氨酸激酶抑制剂 (TKI) 的使用

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...